title: Antiidiotypic antibodies carrying the "internal image" of peptide YIGSR inhibit spontaneous metastasis of Lewis lung carcinoma in mice.
abstract: BACKGROUND
  It has been reported that the laminin derivative synthetic peptide YIGSR can bind to a metastasis-associated laminin receptor and inhibit experimental metastasis. Several antiidiotypic antibody (anti-Id) vaccines have been used in clinical trials with promising results. We used an anti-Id vaccine based on peptide YIGSR for the inhibition of spontaneous metastasis in Lewis Lung carcinoma-bearing mice.
  
  
  METHODS
  High titer anti-YIGSR serum from immunized rabbits was used to immunize sixteen Lewis Lung Carcinoma (LLC)-bearing mice. Another group of sixteen mice (controls) inoculated with LLC was immunized with control rabbit serum. After 24 days of tumor growth, the volume of the tumor was estimated, a blood sample was collected and the lungs were examined macroscopically and microscopically for metastasis. The presence of anti-Id antibodies was detected by Western blotting, ELISA and inhibition of cell attachment assays.
  
  
  RESULTS
  Tumor growth was limited and metastasis was inhibited in the mice that received the anti-Id YIGSR vaccine as compared to controls. Both groups of mice developed anti-rabbit antibodies as indicated by Western blotting. However only the serum of mice immunized with high titer anti-YIGSR rabbit serum (anti-Id YIGSR vaccine) could inhibit the binding of the anti-YIGSR rabbit serum to the peptide YIGSR in ELISA assays. In addition the serum of mice that received the anti-Id YIGSR vaccine but not the controls inhibited cell attachment to the peptide on solid face assays.
  
  
  CONCLUSIONS
  An anti-Id antimetastatic vaccine may be developed based on YIGSR.
authors.affiliation: Department of Histology and Embryology, Medical School Aristotle University, 54006 Thessaloniki, Greece.
authors.forename: Kokkona Kouzi
authors.initials: KK
authors.lastname: Koliakos
authors.forename: Zacharoula
authors.initials: Z
authors.lastname: Sapountzi
authors.forename: Athanassios
authors.initials: A
authors.lastname: Papageorgiou
authors.forename: Varvara
authors.initials: V
authors.lastname: Trachana
authors.forename: Sophia
authors.initials: S
authors.lastname: Kotsinou
authors.forename: George
authors.initials: G
authors.lastname: Koliakos
mesh_terms: D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D015153:Blotting, Western; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D018827:Carcinoma, Lewis Lung / Q000276:immunology / Q000517:prevention & control* / Q000556:secondary; D007797:Laminin / Q000276:immunology*; D008168:Lung / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D009842:Oligopeptides / Q000276:immunology*; D011817:Rabbits
chemical_list: D000888:Antibodies, Anti-Idiotypic; D000970:Antineoplastic Agents; D019496:Cancer Vaccines; D007797:Laminin; D009842:Oligopeptides; C081571:tyrosyl-isoleucyl-glycyl-seryl-arginine